Looks extremely bullish - definitely watching this stock. If price drops to $9, definitely a buy. Australia based firm has some key cancer drugs in the pipeline.
(1) Price above Kumo
(2) Future Kumo bullish
(3) Senkou span A & B with positive slope
(4) Both Tenkan Sen & Kijun Sen have +ve slopes
(5) Chikou Span above the price & free to go up
(6) ADX > 25
US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG
Key Points
With RPDD granted, Kazia may now be eligible to receive a 'rare pediatric disease priority review voucher' (PRV) if paxalisib is approved for DIPG
A PRV grants the holder an expedited six-month review of a new drug application by FDA.
PRVs can be sold to other companies...
Hello,
What is KZIA?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being...
$KZIA
Positive Overall Survival in Glioblastoma Study
Kazia expects to present further data in 2H CY2020
Sales in excess of US$ 1 billion per annum treatment for glioblastoma
Company profile
Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
Kazia Therapeutics Ltd. engages in the development of pharmaceutical drug. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
NASDAQ
